BETA Technologies launches IPO of 25 million shares priced $27-$33
Investing.com - Berenberg has initiated coverage on Pharmanutra SpA (BIT:PHN) with a Buy rating and a price target of EUR85.00, suggesting potential upside of more than 100% from current levels.
The research firm cited Pharmanutra’s leadership position in oral iron supplements as a key factor in its positive outlook, noting the company’s patented Sucrosomial technology and doctor-led business model as competitive advantages.
Berenberg described the company’s business as a hybrid platform that combines pharmaceutical-grade rigor with the scalability characteristics of nutraceuticals, creating a distinctive market position.
The firm expects upcoming quarters to provide greater visibility on Pharmanutra’s new strategic initiatives in the United States and China, where management anticipates significant sales growth within three years.
These international expansion efforts could add "transformational growth" to what Berenberg already considers a resilient European business franchise, according to the research note.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.